Sean G Yates

Dr. Sean G Yates

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2014 in Transfusion
Verified
Journal Article
Closed access
PDF file
SYSean G Yates
Sean G Yates
KMKaren Matevosyan
Karen Matevosyan
CRCynthia Rutherford
Cynthia Rutherford
YSYu‐Min Shen
Yu‐Min Shen
RSRavi Sarode
Ravi Sarode

1 June 2019 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
SASaid Albahra
Said Albahra
SYSean G Yates
Sean G Yates
DJDavid Joseph
David Joseph
NSNicole De Simone
Nicole De Simone
JBJames D. Burner
James D. Burner
RSRavi Sarode
Ravi Sarode

1 April 2021 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
ADAbe DeAnda
Abe DeAnda
GLGal Levy
Gal Levy
MKMichael Kinsky
Michael Kinsky
PSPeni Sanjoto
Peni Sanjoto
MGMary Garcia
Mary Garcia
SYSean G Yates
Sean G Yates

13 January 2020 in Platelets
Verified
Journal Article
Closed access
HSHila Shaim
Hila Shaim
PMPeter McCaffrey
Peter McCaffrey
JTJudy A Trieu
Judy A Trieu
ADAbe DeAnda
Abe DeAnda
SYSean G Yates
Sean G Yates
Desialylation of platelets results in platelet clearance by the Ashwell-Morrell Receptors (AMR) found on hepatocytes. Studies suggest that oseltamivir phosphate inhibits human sialidases, enzymes responsible for desialylation, extending the lifespan of circulating platelets. We thus evaluated, the effects of oseltamivir on platelet count (PC) following treatment. Of the 385 patients evaluated for influenza, 283 (73.5%) were influenza-infected. Of the 283 infected patients, 241 (85.2%) received oseltamivir (I + O+) while 42 patients did not (I + O-). One hundred two non-infected patients received oseltamivir (I-O+). The two groups receiving oseltamivir (I + O+, I-O+), demonstrated a statistically greater increase in the PC (57.53 ± 93.81, p = .013 and 50.79 ± 70.59, p = .023, respectively) relative to the group that did not (18.45 ± 89.33 × 109/L). The observed increase in PC was statistically similar (p = .61) in both groups receiving oseltamivir (I + O+, I-O+), suggesting that this effect is independent of influenza. Comparing clinical characteristics between responders and non-responders to oseltamivir treatment showed that only duration of oseltamivir treatment (AOR = 1.30, 95% CI 1.05–1.61, p = .015) was associated with a positive PC response. Our findings suggest a correlation between oseltamivir treatment and an increase in PCs. Future studies assessing the possible uses of oseltamivir in medical conditions characterized by diminished or defective thrombopoiesis are warranted.

20 November 2015 in Transfusion
Verified
Journal Article
Closed access
PDF file
RJRanjit Joseph
Ranjit Joseph
JBJames Burner
James Burner
SYSean G Yates
Sean G Yates
ASAmanda Strickland
Amanda Strickland
WTWilliam Tharpe
William Tharpe
RSRavi Sarode
Ravi Sarode

28 April 2016 in Transfusion
Verified
Journal Article
Closed access
PDF file
CGChakri Gavva
Chakri Gavva
SYSean G Yates
Sean G Yates
SRSiayareh Rambally
Siayareh Rambally
RSRavi Sarode
Ravi Sarode